http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
안드로겐성 탈모증 환자에서 Scalp Med(R)의유효성 및 안전성 평가에 관한 임상 연구
유박린 ( Bark Lynn Lew ),심우영 ( Woo Young Sim ),허창훈 ( Chang Hun Huh ),박장규 ( Jang Kyu Park ) 대한피부과학회 2008 대한피부과학회지 Vol.46 No.6
Background: Androgenetic alopecia (AGA) is characterized by the structural miniaturization of androgen-sensitive hair follicles in susceptible individuals and is anatomically defined within a given pattern of the scalp. Oral finasteride and topical minoxidil are the only drugs whose effect and safety were demonstrated and approved by the FDA. However, the treatment result of these medications are not always satisfactory. Here, we report the result of a clinical trial of the new topical agent, Scalp med(R) to patients with AGA. Objective: The goal of this study was to test Scalp med(R), the solution including minoxidil, retinol, polysorbate 80 and phytosterol in the treatment of AGA. Methods: Included in this study were males between the ages of 20 and 60 years, in good health, with mild to moderate AGA. Efficacy was evaluated by terminal hair count per 1 cm2 and hair thickness. Results: The results of this clinical trial showed a highly positive response to treatment. After 24 weeks of treatment, a significant improvement in hair count and hair thickness was demonstrated in all the patients. Conclusion: This clinical study establishes the effectiveness and safety of Scalp med(R) in the treatment of AGA. (Korean J Dermatol 2008;46(6):776∼783)
Symposium 6-2 (SYP 6-2) : Recent progress in male pattern hair loss: topical medical treatment
유박린 ( Bark Lynn Lew ) 대한피부과학회 2014 대한피부과학회 학술발표대회집 Vol.66 No.2
Male pattern hair loss(MPHL) is the most common hair loss disorder which can be psychologically disturbing, especially in young men. Treatment options should be cost effective and individualized, as patients often have to bear the full cost of treatment. At present, minoxidil and alfatradiol are the only medical topical treatments approved MPHL in Korea. There are some emerging topical treatment agents, which have a lack of several evidence of study results or treatment effects. Minoxidil was discontinued as an antihypertensive drug because of its side effect of developing significant hypertrichosis. In 1988 it was approved by the FDA for treatment of MPHL as 2% scalp lotion, and subsequently 5% lotion was approved in 1997. The exact mechanism of action of minoxidil is unclear. Its vasorelaxant action is due to the opening of adenosine triphosphate sensitive potassium channels in the vascular smooth muscle cells, which renders the intracellular potential more negative, and this negative gradient promotes depletion of intracellular calcium. In the presence of calcium, the epidermal growth factor has been shown to inhibit follicular growth in vitro. The conversion of minoxidil to minoxidil sulfate (active metabolite) is higher in hair follicles than in the surrounding skin and may suppress epidermal growth factor induced inhibition of growth, prolonging the anagen phase of hair follicles. There is no convincing evidence that minoxidil reverses follicular miniaturization, although it may prevent or delay it. Bimatoprost is a prostaglandin analogue. Lengthening of eyelashes and eyebrows has been observed when prostaglandin analogues are used topically for glaucoma. The precise mechanism of action of prostaglandin analogues is unknown. Bimatoprost 0.03% ophthalmic solution is now approved by the FDA for eyelash hypotrichosis. There is no present evidence to suggest that it can stimulate hair growth over the scalp. Fluridil is a topical antiandrogen used for the treatment of hyperandrogenic skin syndrome. Topical fluridil, owing to its hydrophobicity, dissolves in the sebumand blocks AR in the hair follicles. Fluridil in the aqueous environment rapidly decomposes into fragments that lack hormonal effects. Fluridil has been widely used in Europe but is still awaiting FDA approval in other countries. In a study by Kucerova et al, fluridil has been found to be safe for the treatment of MPHL. And there has been several reports about other topical treatment agents for MPHL.
유박린 ( Bark Lynn Lew ) 대한피부과학회 2014 대한피부과학회 학술발표대회집 Vol.66 No.2
Atopic dermatitis(AD) is a chronic, pruritic inflammatory skin disease that occurs most frequently in children, but also affects many adults. It follows a relapsing course. Topical agents are the mainstay of AD therapy. Even in more severe cases needing systemic or phototherapy, they are often used in conjunction with these modalities. Topical agents from several classes are frequently used in combination, in part because they address different aspects of AD pathogenesis. Topical corticosteroids(TCS) are used in the management of AD in both adults and children and are the mainstay of anti-inflammatory therapy. They act on a variety of immune cells, interfering with antigen processing and suppressing the release of proinflammatory cytokines. They are typically introduced into the treatment regimen after failure of lesions to respond to good skin care and regular use of moisturizers alone. Their efficacy has been demonstrated with more than 110 different RCTs. In addition to decreasing acute and chronic signs of AD, multiple trials have shown decreased pruritus with their application. TCS are used for both active inflammatory disease and for prevention of relapses. Twice-daily application of corticosteroids is generally recommended for the treatment of AD; however, evidence suggests that once-daily application of some corticosteroids may be sufficient. Proactive, intermittent use of topical corticosteroids as maintenance therapy (1-2 times/wk) on areas that commonly flare is recommended to help prevent relapses and is more effective than use of emollients alone. No specific monitoring for systemic side effects is routinely recommended for patientswith AD. Topical calcineurin inhibitors(TCI) are a second class of anti-inflammatory therapy, which inhibit calcineurin dependent T-cell activation, blocking the production of proinflammatory cytokines and mediators of the AD inflammatory reaction. Two TCI are available, topical tacrolimus ointment and pimecrolimus cream. TCI are recommended and effective for acute and chronic treatment, along with maintenance, in both adults and children with AD. Tacrolimus is approved for moderate to severe disease, whereas pimecrolimus is indicated for mild to moderate AD. A meta-analysis found tacrolimus 0.1% to be as effective as the mid-potency TCS, whereas tacrolimus 0.03% is less effective, but more effective than the low-potency TCS. TCI are recommended for use on actively affected areas as a steroid-sparing agent for the treatment of AD. For patients with AD<2 years of age with mild to severe disease, off-label use of 0.03% tacrolimus or 1% pimecrolimus ointment can be recommended. Pimecrolimus cream and tacrolimus ointment may cause skin burning and pruritus, especially when applied to acutely inflamed skin. Initial treatment of patients with AD using topical corticosteroids should be considered to minimize TCI application site reactions. Proactive, intermittent use of TCI as maintenance therapy (2-3 times per week) on areas that commonly flare is recommended to help prevent relapses while reducing the need for topical corticosteroids, and is more effective than the useof emollients alone. No consistent increases in the prevalence of cutaneous viral infections have been seen with continuous or intermittent use of TCI. Routine blood monitoring of tacrolimus and pimecrolimus levels in patients with AD who are applying these agents is not recommended.
Laugier-Hunziker 증후군에서의 구강 색소침착 병변에 대한 고찰
유박린 ( Bark Lynn Lew ),홍경국 ( Kyung Kook Hong ),이상길 ( Sang Kil Lee ),김효종 ( Hyo Jong Kim ),이무형 ( Mu Hyoung Lee ) 대한장연구학회 2005 Intestinal Research Vol.3 No.2
Oral pigmentation is seen fairly commonly in dermatologic practice. Oral pigmentation associated with Laugier-Hunziker syndrome (LHS) is an uncommon condition that shares some dermatologic features with Peutz-Jeghers syndrome (PJS). It is benign and asymptomatic, with no known cause, and is often associated with pigmentation of the nails and other mucosal surfaces. LHS and PJS show very similar skin manifestations but there age of onset, genetics, predilection site and associated systemic disease are different. However, evaluation of intestinal polyps should be performed for accurate differential diagnosis. We present seven patients whose conditions highlight the clinical syndrome known as LHS, and use the opportunity to review its clinical and pathologic features, and the relevant literature. (Intestinal Research 2005;3:145-149)